AstraZeneca reported a Phase 3 win in bladder cancer using a combination built around Imfinzi. The company said combining Imfinzi with Pfizer’s Padcev improved outcomes versus standard of care, and AstraZeneca plans to pursue regulatory approval for the regimen. The report adds to a run of combination successes in oncology that are increasingly designed around immunotherapy backbones plus targeted partner mechanisms. For clinicians and sponsors, the next pressure point is translating topline survival improvements into label-ready evidence packages. AstraZeneca framed its next steps as regulatory-focused following the Phase 3 results update.